L-826266（Cat No.:I007603）is a selective prostaglandin EP4 receptor antagonist developed to modulate inflammatory and immune responses. By inhibiting the EP4 receptor, which mediates PGE₂ signaling, L-826266 reduces inflammation, pain, and tissue remodeling processes. It has been investigated in models of osteoarthritis, rheumatoid arthritis, and cancer, where PGE₂-EP4 signaling plays a pathogenic role. L-826266 is particularly useful for studying the role of prostaglandins in immune regulation, nociception, and tumor progression. Its receptor specificity makes it a valuable tool in dissecting EP4-related pathways.